Cardio-Renal Advisory Committee
Executive Summary
will review Marion's Cardizem SR (diltiazem, sustained release) and Syntex' Cardene (nicardipine) for hypertension, and Lilly's indecainide and Ciba-Geigy's Lopressor (metoprolol) for arrhythmias at its Nov. 3-4 meeting, according to draft agenda.